Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: J Immunol. 2018 Jul 30;201(6):1692–1704. doi: 10.4049/jimmunol.1800244

FIGURE 5.

FIGURE 5.

CLP that expresses a Cebpa +37 kb enhancer/promoter transgene preferentially express Flt3. (A) Representative FC for Flt3, Ly6D, and hCD4 on CLP from Cebpa Enh/prom-hCD4 mice (top); the proportion of CLP that express Flt3 or Ly6D and the proportion of Flt3+, Flt3-, Ly6D+, or Ly6D- CLP that express hCD4 (bottom, mean and SD from three determinations). (B) Representative FC for Flt3 in preproB and proB cells from Cebpa Enh/prom-hCD4 mice. (C) Representative FC for Flt3 and Ly6D on CLP from Cebpa Enh(f/f) and Cebpa Enh(f/f);Mx1-Cre 4 wks after pIpC exposure (top) and the number of total CLP and percent of CLP that express Flt3 or Ly6D (bottom, mean and SD from three determinations). (D) Representative FC for RAG1-GFP in hCD4+ and hCD4- CLP, LSK, hCD4+ and hCD4- preproB, and proB cells, from Cebpa Enh/prom-hCD4::RAG1-GFP mice, with the proportion of cells in the indicated gates (mean and SD from three determinations).